Clinical Trials

Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.

Title Phase Last Update

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [Lu-177]Lu-PSMA-617 in Chinese Adult Male Patients with Progressive PSMA-Positive mCRPC

Phase 2

Last update: February 13

Phase 2 February 13

Testing the Addition of Sunitinib Malate to Lutetium Lu-177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Phase 1

Last update: February 13

Phase 1 February 13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 2

Last update: February 13

Phase 2 February 13

Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2

Last update: February 13

Phase 2 February 13

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu-177 Dotatate), Compared to Lutetium Lu-177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2

Last update: February 13

Phase 2 February 13

Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1

Last update: February 13

Phase 1 February 13

A Phase II Study of AAA617 Alone and AAA617 in Combination with ARPI in Patients with PSMA PET Scan Positive CRPC (PSMACare)

Phase 2

Last update: February 13

Phase 2 February 13

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men with Advanced Prostate Cancer with Bone Metastasis

Phase 1

Last update: February 13

Phase 1 February 13

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors

Phase 1

Last update: February 13

Phase 1 February 13

Copper Cu-64-DOTA-Trastuzumab PET in Predicting Response to Treatment with Ado-Trastuzumab Emtansine in Patients with Metastatic HER2 Positive Breast Cancer

N/A

Last update: February 13

N/A February 13